1. Nek2 Is a Novel Regulator of B Cell Development and Immunological Response
   Zhimin Gu et al, 2014, BioMed Research International CrossRef
2. Upregulation of NEK2 is associated with drug resistance in ovarian cancer
   XIA LIU et al, 2014 CrossRef
3. Downregulation of NEK11 is associated with drug resistance in ovarian cancer
   XIA LIU et al, 2014 CrossRef
4. miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer
   MEISI YAN et al, 2016 CrossRef
5. Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.
   Brendan Frett et al, 2014, J Med Chem CrossRef
6. Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation
   Terrick Andey et al, 2015, Mol. Pharmaceutics CrossRef
7. High NEK2 confers to poor prognosis and contributes to cisplatin-based chemotherapy resistance in nasopharyngeal carcinoma.
   He Xu et al, 2019, J Cell Biochem CrossRef
8. Prognostic significance of NEK2 in human solid tumors: a systematic review and meta-analysis
   Xichen Wang et al, 2019, Biosci. Rep. CrossRef
9. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.
   P Cappello et al, 2014, Oncogene CrossRef
10. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin
    Honghong Shen et al, 2019, J Exp Clin Cancer Res CrossRef
11. NIMA related kinase 2 promotes gastric cancer cell proliferation via ERK/MAPK signaling
    Wei-Dong Fan et al, 2019, WJG CrossRef
12. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells
    Jaehyung Lee et al, 2013, Cell Cycle CrossRef
13. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer
    Yan-Ru Zeng et al, 2015, BMC Urol CrossRef
14. Targeting NEK2 as a promising therapeutic approach for cancer treatment.
    Yanfen Fang et al, 0 CrossRef
15. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression
    Sheng-Ming Wu et al, 2017, Int. J. Cancer CrossRef
16. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2
    Jia Wang et al, 2017 CrossRef
17. Deciphering the roles of lncRNAs in breast development and disease
    John Lalith Charles Richard et al, 2018, Oncotarget CrossRef
18. Long Non-Coding RNA HOTAIR in Breast Cancer Therapy
    Monica Cantile et al, 2020, Cancers CrossRef
19. Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity
    Yanfen Fang et al, 2016, Oncotarget CrossRef
20. Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo[1,2-a] pyridine derivatives as Nek2 Inhibitors
    Haili Wang et al, 2020, Bioorganic & Medicinal Chemistry CrossRef
21. Combinational treatments for breast cancer
    Omid Tavallaei et al, 2020, J Rep Pharma Sci CrossRef
22. The role of tumor suppressor short non-coding RNAs on breast cancer
    Shokooh Salimimoghadam et al, 2021, Critical Reviews in Oncology/Hematology CrossRef
23. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells
    Yainyrette Rivera-Rivera et al, 2021, Sci Rep CrossRef
24. Study of mangal based naphthoquinone derivatives anticancer potential towards chemo-resistance related Never in mitosis gene A-related kinase 2-Insilico approach
    K. Archana Vasuki et al, 2021, Molecular Simulation CrossRef
25. AURKB, CHEK1 and NEK2 as the Potential Target Proteins of Scutellaria barbata on Hepatocellular Carcinoma: An Integrated Bioinformatics Analysis
    Chaoyuan Huang et al, 2021, IJGM CrossRef
26. null
    Luna Acharya et al, 2021 CrossRef
27. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells
    Chiara Naro et al, 2021, J Exp Clin Cancer Res CrossRef
28. Integrative Analysis of the Expression Levels and Prognostic Values for NEK Family Members in Breast Cancer
    Wen-Liang Gao et al, 2022, Front. Genet. CrossRef
29. NEK2 is associated with poor prognosis of clear cell renal cell carcinoma and promotes tumor cell growth and metastasis
    Xiaoli Feng et al, 2022, Gene CrossRef
30. siRNA and targeted delivery systems in breast cancer therapy
    Sepideh Mirzaei et al, 2022, Clin Transl Oncol CrossRef
31. Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer
    Zhonghan Wu et al, 2023, International Immunopharmacology CrossRef
32. Identification of a novel spirocyclic Nek2 inhibitor using high throughput virtual screening
    Ashif I. Bhuiyan et al, 2023, Bioorganic & Medicinal Chemistry Letters CrossRef
33. BrcaDx: precise identification of breast cancer from expression data using a minimal set of features
    Sangeetha Muthamilselvan et al, 2023, Front. Bioinform. CrossRef
34. NEK2 promotes esophageal squamous cell carcinoma cell proliferation, migration and invasion through the Wnt/β-catenin signaling pathway
    Dong Guo et al, 2023, Discov Onc CrossRef
35. Behavior of intracellular lipid droplets during cell division in HuH7 hepatoma cells
    Tomohiko Makiyama et al, 2023, Experimental Cell Research CrossRef
36. Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
    Marco Jessen et al, 2024, Oncogene CrossRef
37. Natural Compounds and Breast Cancer: Chemo-Preventive and Therapeutic Capabilities of Chlorogenic Acid and Cinnamaldehyde
    Yusuff Olayiwola et al, 2024, Pharmaceuticals CrossRef